Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

The structure of ApoE has proven tricky to discern in its native state, namely, attached to lipoproteins. Now, scientists led by David Holtzman at Washington University in St. Louis have captured ...

Very high lipoprotein(a) levels strongly predicted long-term cardiovascular disease risk in healthy women, according to a cohort study, while mild to moderately high levels were not really red flags.

Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular events in initially healthy women. Subscribe to our newsletter for the ...